Amarin Corporation PLC
NASDAQ:AMRN
Amarin Corporation PLC
Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. The firm is focused on the commercialization and development of therapeutics for cardiovascular disease management. The firm operates through the development and commercialization of Vascepa segment. Its lead product, Vascepa (icosapent ethyl) capsule for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The firm sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. The firm is focused on the commercialization and development of therapeutics for cardiovascular disease management. The firm operates through the development and commercialization of Vascepa segment. Its lead product, Vascepa (icosapent ethyl) capsule for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The firm sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
Revenue Growth: Amarin reported total net revenue of $49.7 million for Q3 2025, up 17% year-over-year, primarily driven by higher U.S. sales.
US Market Share: VASCEPA maintained over 50% share of the IPE market in the U.S., retaining major exclusive accounts and regaining exclusive status with a large pharmacy benefit manager.
Cost Reductions: The company began realizing restructuring-related OpEx savings, with SG&A expenses down 47% year-over-year.
European Transition: The commercialization transition to Recordati in Europe is progressing smoothly and is expected to be fully complete by the end of 2025, with early end-market demand growth seen.
Operating Margin Improvement: Operating margin improved to negative 22% in Q3 2025 from negative 60% a year ago, reflecting a more efficient, rightsized business.
Cash Position: Amarin ended the quarter with $286.6 million in cash and investments and no debt.
Free Cash Flow Outlook: Management expects to achieve positive free cash flow in 2026.
FDA Label Update: The FDA revised fenofibrate labeling to specify lack of cardiovascular benefit, which management views as supporting VASCEPA’s differentiated position.
